

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Ascension Borgess Allegan Hospital</p>	<p>In accordance with letter dated April 20, 2020,</p>	<p>4. Expiration Date: February 28, 2021</p>
<p>2. 555 Linn St. Allegan, MI 49010</p>	<p>3. License No.: 21-18659-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-14003 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Gadolinium-153 permitted by 10 CFR 35.500	D. Sealed Sources (North American Scientific, Inc., Model 3601)	D. Four sources; 250 millicuries per source and 1 curie total	D. For possession and storage only with intent to dispose.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-18659-01

Docket or Reference No.:  
030-14003

Amendment No. 26

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 555 Linn St., Allegan, Michigan, 49010.
11. The Radiation Safety Officer (RSO) for this license is Philip J. Hartgerink, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D.,D.O.,etc.)</u> | <u>Material and Use</u>                                                                                                                    |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Dennis A. Bruce, M.D.                   | 10 CFR 35.100,10 CFR 35.200                                                                                                                |
| Philip J. Hartgerink, M.D.              | 10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less) |
| Michael Jacoby, M.D.                    | 10 CFR 35.100,10 CFR 35.200                                                                                                                |
| Michael S. Pawlick, D.O.                | 10 CFR 35.100,10 CFR 35.200                                                                                                                |
| Ramon Raneses, M.D.                     | 10 CFR 35.200                                                                                                                              |
| Joel H. Reinoehl, M.D.                  | 10 CFR 35.200                                                                                                                              |
| Christopher Rogers, D.O.                | 10 CFR 35.200                                                                                                                              |
| John Schonder, M.D.                     | 10 CFR 35.200                                                                                                                              |
| Eric E. Ward, M.D.                      | 10 CFR 35.100,10 CFR 35.200                                                                                                                |
| Douglas J. Wunderly, M.D.               | 10 CFR 35.200                                                                                                                              |
13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License No.: 21-18659-01

Docket or Reference No.:  
030-14003

Amendment No. 26

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 26, 2010 (ML103010512)
- B. Letter dated October 6, 2014 (ML14287A674)
- C. Letter dated May 30, 2017 (ML17157B613)
- D. Letter dated July 6, 2017 (ML17187A635)
- E. Letter dated August 27, 2019 (ML19239A268)
- F. Letter dated April 15, 2020 (ML20108E861)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: July 2, 2020

By: \_\_\_\_\_

Laura B. Cender  
Region 3